- Home
- PRHI vs EDSA Comparison
PRHI vs EDSA Comparison
Compare PRHI & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRHI | EDSA |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PRHI | EDSA |
|---|---|---|
| Price | $0.72 | $1.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 25.8K | ★ 170.4K |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.91 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $0.72 |
| 52 Week High | $2.83 | $2.95 |
Technical Indicators
Market Signals| Indicator | PRHI | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 32.00 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $1.57 |
| Average True Range (ATR) | 0.00 | 0.15 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 38.50 |
Price Performance
Historical ComparisonAbout PRHI Presurance Holdings Inc.
Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.